EX-99.1 2 exh991q32019earningsrelease.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1

xerislpharmrgba11.jpg    
                                



XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS
Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription
MAA for ready-to-use glucagon on track for submission to EMA by year-end
Data from three Phase 2 studies expected by year-end

CHICAGO, IL; November 7, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced financial results for the third quarter and nine months ended September 30, 2019.
 
“We’ve reached one of our most significant milestones as a company during the third quarter of 2019 - our first U.S. FDA approval of Gvoke - the first pre-mixed, pre-filled, pre-measured liquid stable glucagon to treat severe hypoglycemia. With Gvoke, people with diabetes and caregivers now have a solution that they can count on. I am very encouraged with the reception and enthusiasm of the diabetes community for this important new advancement,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals. “Next week we will commence the commercial launch of Gvoke PFS. In addition to calling on healthcare professionals, we will continue to focus our efforts for the balance of 2019 on obtaining managed care coverage to enable access to Gvoke for patients,” Mr. Edick continued, “Looking ahead over the next few months, we also expect to report data from several clinical programs that may further support the potential and breadth of our formulation technology platforms.”


Third Quarter 2019 Highlights, Recent and Upcoming Events

Ready-to-use Glucagon Programs

- Xeris will begin its commercial launch of Gvoke pre-filled syringe (PFS), its ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above, in the U.S. in mid-November. Xeris’ salesforce will begin calling on healthcare professionals with an additional focus on enabling formulary inclusion and patient access. Gvoke PFS is now available by prescription for home delivery (powered by PillPack, an Amazon company) and at local pharmacies through their preferred wholesalers. The Company still expects to launch Gvoke HypoPenTM in 2020.

- Xeris expects to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) by the end of 2019 for its ready-to-use liquid stable glucagon.

- Xeris expects data from the in-clinic portion of its Phase 2 study of post-bariatric hypoglycemia (PBH) before year-end.






- Xeris expects data from the in-clinic portion of its Phase 2 study of exercise-induced hypoglycemia (EIH) before year-end.

- Xeris has completed enrollment in its Phase 2 study of hypoglycemia-associated autonomic failure (HAAF). Data from the 28-day treatment period of this study is expected by year-end.

Other XeriSolTM Programs

- Xeris began dosing patients with Type 1 diabetes in a Phase 2 clinical study to evaluate its investigational ready-to-use, fixed-ratio co-formulation of pramlintide and insulin in patients with diabetes. Data from this study is anticipated in the first half of 2020.

- Xeris has initiated a weight-based dosing study in healthy volunteers of its investigational ready-to-use diazepam formulation. Data from this study is expected in the first half of 2020.

Corporate

- Xeris expanded its debt facility to $85 million with Oxford Finance and Silicon Valley Bank which provides an interest-only period of up to three years and an extension of the maturity date.

- Xeris’ senior management will participate in a fireside chat at the Jefferies London Healthcare Conference on November 21, 2019 at 8:00 a.m. local time. Access to the live webcast and subsequent archived presentation will be available on the investor section of the Company’s website.

Third Quarter and Year-to-Date 2019 Financial Highlights

Cash position: As of September 30, 2019, Xeris reported total cash, cash equivalents, and investments (collectively, “cash and investments”) of $116.4 million, compared to $112.6 million at December 31, 2018.

Research and development (R&D) expenses: R&D expenses for the three and nine months ended September 30, 2019 were $15.5 million and $48.0 million, respectively, compared to $10.9 million and $28.3 million for the three and nine months ended September 30, 2018, respectively. The increases were primarily driven by manufacturing costs related to Gvoke prior to commercialization, increased expenses associated with Xeris' clinical and preclinical trials and increased personnel expenses. 

Selling, general and administrative (SG&A) expenses: SG&A expenses for the three and nine months ended September 30, 2019 were $14.9 million and $42.4 million, respectively, compared to $4.7 million and $12.4 million for the three and nine months ended September 30, 2018, respectively. The increases were driven by increased marketing and selling expenses and increased personnel expenses primarily to support commercialization efforts of Gvoke.

Net loss: For the three months ended September 30, 2019, Xeris reported a net loss of $32.8 million, or $1.22 per share, compared to a net loss of $14.8 million, or $0.71 per share, for the same period in 2018. For the nine months ended September 30, 2019, Xeris reported a net loss of $92.5 million, or $3.58 per share, compared to a net loss of $39.7 million, or $4.36 per share, for the same period in 2018.

About Xeris Pharmaceuticals, Inc.

Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.




With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Xeris Pharmaceuticals, Inc., including statements regarding the acceptance of Gvoke™ in the marketplace, the market and therapeutic potential of its product candidates, expectations regarding clinical data, the timing or likelihood of commercialization of its product candidates, the potential utility of its formulation platforms and other statements containing the words "will," "would," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, without limitation, the regulatory approval of its product candidates, its ability to market and sell its products, if approved, and other factors discussed in the "Risk Factors" section of the most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Xeris’ subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Xeris expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.


Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
312-736-1237







XERIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

 
September 30, 2019
 
December 31, 2018
 
(unaudited)
 
 
Assets
 
 
 
Current assets:
 
 
 
   Cash and cash equivalents
$
56,160

 
$
45,716

   Short-term investments
46,311

 
66,917

   Accounts receivable, net
874

 
2,869

   Prepaid expenses and other current assets
2,631

 
2,397

      Total current assets
105,976


117,899

Investments
13,913

 
—

Property and equipment, net
7,952

 
2,034

Other assets
259

 
95

      Total assets
$
128,100


$
120,028

 
 
 
 
Liabilities and Stockholders' Equity
 
 
 
Current liabilities:
 
 
 
   Accounts payable
$
1,678

 
$
866

   Accrued expenses
15,706

 
8,214

   Warrant liabilities
302

 
860

   Deferred grant awards
106

 
232

      Total current liabilities
17,792


10,172

Long-term debt, net of unamortized deferred costs
58,124

 
31,890

Other liabilities
8,528

 
2,560

      Total liabilities
84,444


44,622

Total stockholders' equity
43,656

 
75,406

      Total liabilities and stockholders' equity
$
128,100


$
120,028







XERIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data; unaudited)

 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2019
 
2018
 
2019
 
2018
Grant income
 
$
314

 
$
582

 
$
843

 
$
1,611

Service revenue
 
9

 
—

 
48

 
53

Cost of revenue
 
10

 
—

 
33

 
42

         Gross profit
 
313

 
582

 
858

 
1,622

Operating expenses:
 
 
 
 
 
 
 
 
Research and development
 
15,518

 
10,875

 
48,018

 
28,264

Selling, general and administrative
 
14,877

 
4,650

 
42,419

 
12,388

Expense from operations
 
30,395

 
15,525

 
90,437

 
40,652

Loss from operations
 
(30,082
)
 
(14,943
)
 
(89,579
)
 
(39,030
)
Other income (expense):
 
 
 
 
 
 
 
 
Interest and other income
 
657

 
462

 
2,173

 
796

Interest expense
 
(3,507
)
 
(737
)
 
(5,632
)
 
(1,490
)
Change in fair value of warrants
 
96

 
451

 
540

 
63

Total other income (expense)
 
(2,754
)
 
176

 
(2,919
)
 
(631
)
Net loss
 
$
(32,836
)
 
$
(14,767
)
 
$
(92,498
)
 
$
(39,661
)
 
 
 
 
 
 
 
 
 
Net loss per common share - basic and diluted
 
$
(1.22
)
 
$
(0.71
)
 
$
(3.58
)
 
$
(4.36
)
 
 
 
 
 
 
 
 
 
Weighted average common shares
   outstanding, basic and diluted
 
26,942,591

 
20,714,475

 
25,810,113

 
9,104,491